Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Glioblastoma × defactinib × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Myelodysplastic Syndromes 1 Melanoma 1 Lung Neoplasms 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1 Brain Neoplasms 1 Advanced Colorectal Cancer 1 Adenocarcinoma of Lung 1

Interventions

Temozolomide 40 Radiotherapy 18 Magnetic Resonance Spectroscopy 12 pembrolizumab 11 Specimen Handling 10 Lomustine 10 Bevacizumab 10 Radiation 7 Cyclophosphamide 5 fludarabine 4 Nivolumab 4 Aminolevulinic Acid 4 Transurethral Resection of Bladder 3 Surgical Procedures, Operative 3 Ipilimumab 3 regorafenib 2 olaparib 2 fluciclovine F-18 2 atezolizumab 2 antisecretory factor 2 abemaciclib 2 Standard of Care 2 Restraint, Physical 2 Re-Irradiation 2 Radiotherapy, Intensity-Modulated 2 Palliative Care 2 Oncolytic Virotherapy 2 ONC206 2 Metformin 2 Leukapheresis 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06630260 2026-01-21

5G-RUBY

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡